Pharmacists in Office: November Results

Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.

Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.

Pharmacists expand access with no-appointment care but face state laws limiting test-to-treat for COVID-19 and flu, fueling calls for advocacy.

AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.

Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.

Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.

This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.

Cheri Schmit explains how pharmacists' roles are growing beyond dispensing into prevention, test-and-treat, and artificial intelligence-supported patient care.